MedTrace Logo

Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

NCT02410369 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-12-21

No results posted yet for this study

Summary

In this clinical study, the investigators evaluate the efficacy and safety of S-588410 in patients who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

Conditions

  • Non-small- Cell Lung Cancer

Interventions

DRUG

S-588410

Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.

DRUG

Placebo

Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.

Sponsors & Collaborators

  • Kanagawa Cancer Center

    collaborator UNKNOWN

  • National Cancer Center Hospital East

    collaborator OTHER

  • Shiga University of Medical Science

    collaborator UNKNOWN

  • Fukushima Medical University

    collaborator OTHER

  • Hokkaido University

    collaborator OTHER

  • Shionogi

    collaborator INDUSTRY

  • Tokyo University

    lead OTHER

Principal Investigators

  • Yataro Daigo, MD, PhD · Institute of Medical Science, The University of Tokyo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2020-03-31
Completion
2021-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02410369 on ClinicalTrials.gov